New and Improved: The Latest Research in Disease Screening
New ideas and innovations look beyond conventional screening options to facilitate improved disease diagnosis and patient outcomes
Top of the News-dtet
Generalizing Genomics Learning
A new NIH network aims to remove barriers and share knowledge to drive more widespread adoption of genomics in clinical settings
Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
Association Representatives Say PAMA is #1 Concern for Lab Industry
From - Diagnostic Testing & Emerging Technologies
In the kick-off event of G2 Intelligence's 2017 Laboratory Institute (Washington D.C.; Oct. 25-27), representatives of the biggest laboratory-related associations shared…
Payers Turning to Automated Pre-Approval Systems for Genetic Tests
...
Already a member? Log in here
2017 Looking Good for Health Care Investment;
Diagnostic Industry Poised for Large, Future Exits
From - Diagnostic Testing & Emerging Technologies
So far, 2017 is proving to be a good year for fundraising and investment in the broad health care industry, according to report by…
Draft 2018 CLFS Reveals Fundamental Flaws in PAMA Reporting Exercise; Time to Take Action
By Lâle White bio
As XIFIN predicted, the PAMA reporting exercise has resulted in significant proposed laboratory fee cuts. In fact…
Two App Marketplaces Ramping Up Consumer Genomics Offerings
...
Already a member? Log in here
Companion Diagnostics Driving New Model for Pharma-Dx Partnerships
US oncology patients are missing out on targeted therapies due to a combination of testing "quality gaps" and slow test diffusion
FDA Approves First Companion Diagnostic Panel
...
Already a member? Log in here
FDA Reports Progress in Advancing Regulatory Science for Diagnostics
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) recently unveiled its FY 2015-2016: Regulatory Science Progress Report. The report, the second of its kind under the…
FDA Speeding Approval Process, Continued User Fees Needed
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) is plagued with chronic understaffing, scrutiny over the length of time for approvals, and an expanding workload, while also…
Genomic Markers May ID Risk of Chemo Side Effects
From - Diagnostic Testing & Emerging Technologies
While much attention is focused on using genomic markers to target the effectiveness of treatments, simultaneous research is exploring use of genomic markers to…
